Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial
ABSTRACT NIM‐1324 is an oral investigational new drug for autoimmune disease that targets the Lanthionine Synthetase C‐like 2 (LANCL2) pathway. Through activation of LANCL2, NIM‐1324 modulates CD4+ T cells to bias signaling and cellular metabolism toward increased immunoregulatory function while pro...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/cts.70129 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|